Ulcerative Colitis (UC) Market in China 2023
This industry report offers market estimates of the China market, followed by a detailed analysis of the type, and product. The China market data on ulcerative colitis can be segmented by type: mild ulcerative colitis, moderate to severe ulcerative colitis. Ulcerative colitis market is further segmented by product: infliximab, mesalazine, sulfasalazine (SSZ), others.
As of 2022, the major players in the China ulcerative colitis market were Losan Pharma GmbH, Ferring Holding SA, Guangdong Qiangji Pharmaceutical Co. Ltd., Janssen Pharmaceuticals Inc., Shanghai Sine Tianping Pharmaceutical Co. Ltd.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive coverage of the market across different market segments, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
Get a detailed picture of the China Ulcerative Colitis Market
Identify segments/areas to invest in over the forecast period in the China Ulcerative Colitis Market
Understand the competitive environment, the markets leading players
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
Part 2. Introduction
Study period
Geographical scope
Market segmentation
Part 3. Ulcerative colitis market overview
Part 4. Market breakdown by type
Mild ulcerative colitis
Moderate to severe ulcerative colitis
Part 5. Market breakdown by product
Infliximab
Mesalazine
Sulfasalazine (SSZ)
Others
Part 6. Key companies
Losan Pharma GmbH
Ferring Holding SA
Guangdong Qiangji Pharmaceutical Co., Ltd.
Janssen Pharmaceuticals, Inc.
Shanghai Sine Tianping Pharmaceutical Co., Ltd.
Part 7. Methodology
Global Inflammatory Bowel Disease (IBD) Market – Analysis By Disease Indication (Crohn’s Disease, Ulcerative Colitis), Drug Class, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Pandemic, Competition and Forecast (2021-2026)
Executive Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and
USD 2400 View ReportUlcerative Colitis - Global Drug Forecast and Market Analysis to 2029
Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2029Ulcerative colitis (UC) is a type of inflammatory bowel disease. In UC, chronic inflammation affects the colon (also known as
USD 10995 View ReportGlobal Inflammatory Bowel Disease (IBD) Market – Analysis By Disease Indication (Crohn’s Disease, Ulcerative Colitis), Drug Class, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Pandemic, Competition and Forecast (2021-2026)
Executive Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and
USD 2400 View ReportUlcerative Colitis - Global Drug Forecast and Market Analysis to 2029
Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2029Ulcerative colitis (UC) is a type of inflammatory bowel disease. In UC, chronic inflammation affects the colon (also known as
USD 10995 View ReportFill The Form For Sample Request